ArticleTherapeutic advances in psychopharmacology2021
Within-treatment changes in a novel addiction treatment program using traditional Amazonian medicine.
Article in Therapeutic advances in psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Reported Safety Practices of Publicly Advertised Psychedelic Retreats.JAMA network open · 2026Article
- Exploring Colombian medicinal flora used in indigenous and campesino health systems for neuropsychiatric disorders and neuropharmacological potential: an ethnopharmacological review.Frontiers in pharmacology · 2026Review
- Self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities.Addiction (Abingdon, England) · 2025Article
- Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors.Cellular and molecular life sciences : CMLS · 2024Review
- A quantitative textual analysis of the subjective effects of ayahuasca in naïve users with and without depression.Scientific reports · 2023Article
- Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic.Scientific reports · 2023Article
- The Canadian Psychedelic Survey: Characteristics, Patterns of Use, and Access in a Large Sample of People Who Use Psychedelic Drugs.Psychedelic medicine (New Rochelle, N.Y.) · 2023Article
- Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder.Frontiers in pharmacology · 2023Review
- Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting.The International journal on drug policy · 2022Article
- Psychedelic Therapies at the Crossroads of Trauma and Substance Use: Historical Perspectives and Future Directions, Taking a Lead From New Mexico.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe therapeutic use of psychedelics is regaining scientific momentum, but similarly psychoactive ethnobotanical substances have a long history of medical (and other) uses in indigenous contexts. Here we aimed to evaluate patient outcomes in a residential addiction treatment center that employs a novel combination of Western and traditional Amazonian methods.
methodsThe study was observational, with repeated measures applied throughout treatment. All tests were administered in the center, which is located in Tarapoto, Peru. Data were collected between 2014 and 2015, and the study sample consisted of 36 male inpatients who were motivated to seek treatment and who entered into treatment voluntarily. Around 58% of the sample was from South America, 28% from Europe, and the remaining 14% from North America. We primarily employed repeated measures on a psychological test battery administered throughout treatment, measuring perceived stress, craving frequency, mental illness symptoms, spiritual well-being, and physical and emotional health. Addiction severity was measured on intake, and neuropsychological performance was assessed in a subsample from intake to at least 2 months into treatment.
resultsStatistically significant and clinically positive changes were found across all repeated measures. These changes appeared early in the treatment and were maintained over time. Significant improvements were also found for neuropsychological functioning.
conclusionThese results provide evidence for treatment safety in a highly novel addiction treatment setting, while also suggesting positive therapeutic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.